Home/Filings/4/0001209191-19-020763
4//SEC Filing

Went Gregory T 4

Accession 0001209191-19-020763

CIK 0001328143other

Filed

Mar 20, 8:00 PM ET

Accepted

Mar 21, 4:37 PM ET

Size

6.0 KB

Accession

0001209191-19-020763

Insider Transaction Report

Form 4
Period: 2019-03-20
Went Gregory T
DirectorChief Executive Officer10% Owner
Transactions
  • Sale

    Common Stock

    2019-03-20$7.99/sh6,319$50,489176,291 total
Holdings
  • Common Stock

    (indirect: By Trust)
    199,242
Footnotes (2)
  • [F1]Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
  • [F2]The shares were sold at prices ranging from $7.94 to $8.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Issuer

Adamas Pharmaceuticals Inc

CIK 0001328143

Entity typeother

Related Parties

1
  • filerCIK 0001604541

Filing Metadata

Form type
4
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 4:37 PM ET
Size
6.0 KB